| Biotechnology Industry | Healthcare Sector | Dr. Jong-Yoon Chun CEO | KRX SM Exchange | KR7096530001 ISIN |
| South Korea Country | 63 Employees | 29 Jun 2026 Last Dividend | 23 Apr 2021 Last Split | - IPO Date |
Seegene, Inc. is a globally renowned company in the molecular diagnostics market, specializing in the development and manufacture of a wide array of diagnostics products. The company focuses on delivering innovative solutions for the detection of infectious diseases, including respiratory, gastrointestinal, and sexually transmitted infections, human papillomavirus, tuberculosis, and sepsis, among others. It also ventures into the detection of genetic mutations such as SNPs in significant genes. Established in the year 2000, Seegene has positioned itself as a leader in molecular diagnostics, leveraging cutting-edge technologies to provide reliable and efficient diagnostic tests. Headquartered in Seoul, South Korea, Seegene operates worldwide, significantly contributing to global health by facilitating early and accurate disease diagnosis. The company's strategic collaborations, such as with Werfen for the joint development of syndromic qPCR assays, highlight its commitment to advancing diagnostic solutions through partnerships and innovation.